Announcements Trials
Browse Landscape

Status

Completed 4Unknown 3Recruiting 2Available 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

tempol 2balstilimab 2zolbetuximab 1zipalertinib 1venetoclax 1ulixertinib 1tisagenlecleucel 1tipifarnib 1tebentafusp 1talazoparib 1sodium thiosulfate 1selinexor 1ruxolitinib 1ribociclib 1osunprotafib 1nirogacestat 1mirdametinib 1lifileucel 1leronlimab 1idecabtagene vicleucel 1gedatolisib 1ensartinib 1dodecyl maltoside 1burosumab 1brexucabtagene autoleucel 1belantamab mafodotin 1axicabtagene ciloleucel 1asciminib 1anlotinib 1TEMPOL-H 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Available × INDUSTRY × ensartinib × Clear all
NCT04146571 2022-10-20

Expanded Access to Ensartinib for Participants With ALK+ NSCLC

Xcovery Holdings, Inc.

Available
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡